{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.0","upperLimit":"1.0","value":"1.0"},{"groupId":"OG001","lowerLimit":"0.9","upperLimit":"7.4","value":"1.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"description":"Time to PR or Better response was defined as duration from the date of first dose (start of induction) to the date of initial documentation of the response (PR or better) which was confirmed by a repeated measurement as required by the IMWG criteria. PR is defined as per IMWG criteria as \\>= 50% reduction of serum M-protein and reduction in 24 hours urinary M-protein by \\>= 90% or to \\< 200 mg/24hours. If the serum and urine M-protein are unmeasurable, a\\>= 50% decrease in the difference between involved and uninvolved Free light chain (FLC) levels is required in the place of the M-protein criteria. If serum and urine M-protein are not measurable, and serum free light assay is also not measurable, \\>=50% reduction in plasma cells is required in place of M-protein, provided baseline bone marrow plasma cells percentage was \\>=30%. In addition to the above listed criteria, if present at baseline, a \\>= 50% reduction in the size of soft tissue plasmacytomas is also required.","dispersionType":"95% Confidence Interval","groups":[{"description":"Induction therapy:Participants received daratumumab, cyclophosphamide, bortezomib, and dexamethasone (Dara-CyBorD) as: daratumumab 8 mg/kg IV on Cycle 1(Day 1,2) and 16 mg/kg IV on Cycle 1(Days 8,15,22), Cycle 2 (Days 1,8,15,22), Cycles 3-6 (Days 1,15), Cycles 7-8(Day 1); Cyclophosphamide 300 mg/m\\^2 orally on Days 1,8,15,22 of each cycle (28 days); Bortezomib 1.5 mg/m\\^2 SC on Days 1,8,15 of each cycle; Dexamethasone 20 mg IV on Cycle 1(Day1,2,8,15,22) and orally on Cycle 1(Day 9,16,23), 40 mg IV or oral on Cycle 2 (Days 1,8,15,22), Cycle 3-8 (\\[if with CyBorD\\] Days 1,8,15,22). Consolidation therapy (CT):Participants who were considered eligible for transplant underwent autologous stem cell transplantation \\[ASCT\\] at investigator discretion. Maintenance therapy:Daratumumab 16 mg/kg IV on Day 1 for 12 cycles or until PD, whichever occurred first; Dexamethasone 12 mg IV or oral on Day 1 of each cycle(for ASCT participants, maintenance therapy was to begin approximately 90 days after ASCT).","id":"OG000","title":"Newly Diagnosed Multiple Myeloma (NDMM)"},{"description":"Participants with RMM (defined as having achieved at least a PR with first-line therapy before progression) received treatment as-Induction therapy:Participants received Dara-CyBorD as: daratumumab 8 mg/kg IV on Cycle 1(Day 1,2) and 16 mg/kg IV on Cycle 1(Days 8,15,22),Cycle 2 (Days 1,8,15,22),Cycles 3-6(Days 1,15),Cycles 7-8(Day 1); Cyclophosphamide 300 mg/m\\^2 orally on Days 1,8,15,22 of each cycle (28 days); Bortezomib 1.5 mg/m\\^2 SC on Days 1,8,15 of each cycle; Dexamethasone 20 mg IV on Cycle 1(Day1,2,8,15,22) and orally on Cycle 1(Day 9,16,23), 40 mg IV or oral on Cycle 2(Days 1,8,15,22),Cycle 3-8 (\\[if with CyBorD\\] Days 1,8,15,22). CT: Participants who were considered eligible for transplant underwent ASCT at investigator discretion. Maintenance therapy:Daratumumab 16 mg/kg IV on Day 1 for 12 cycles or until PD, whichever occurred first; Dexamethasone 12 mg IV or oral on Day 1 of each cycle(for ASCT participants, maintenance therapy was to begin approximately 90 days after ASCT).","id":"OG001","title":"Relapsed Multiple Myeloma (RMM)"}],"paramType":"MEDIAN","populationDescription":"Response-evaluable set includes all enrolled participants who had measurable disease, received at least 1 dose of study treatment, and had at least 1 efficacy evaluation assessment.","reportingStatus":"POSTED","timeFrame":"Up to 12 months","title":"Time to Partial Response (PR) or Better","type":"SECONDARY","unitOfMeasure":"Months"}